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Systemic and vascular inflammation are thought to be key mechanisms underlying the 
increased risk of cardiovascular disease (CVD) in those with HIV-infection [1, 2]. 
Antiretroviral therapy (ART) reduces, but does not necessarily normalize, systemic 
inflammation [3]. As such, adjunctive strategies to further reduce inflammation may be 
helpful in mitigating the risk of CVD in HIV.
In a single-arm, open-label, eight week, pilot study, we reported that pentoxifylline (PTX) 
reduced circulating levels of interferon-γ-induced protein 10 (IP-10) and soluble vascular 
cell adhesion molecule-1 (sVCAM-1) and improved endothelial function (measured as flow-
mediated dilation (FMD) of the brachial artery) in HIV-infected patients not receiving ART 
[4]. However, in a randomized, placebo-controlled trial of PTX in a similarly untreated 
population, we did not confirm that PTX reduced inflammation or improved endothelial 
function [5]. In fact, PTX unexpectedly led to significantly increased circulating soluble 
tumor necrosis factor-1 (sTNFR1) levels compared to placebo in this trial. However, the 
potential effects of PTX on FMD and inflammation in a population initiating ART are 
unknown. Thus, we conducted a randomized, placebo-controlled, single-center pilot trial of 
PTX 400mg thrice daily given for 48 weeks in patients concurrently initiating ART 
(ClinicalTrials.gov NCT00864916).
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The eligibility criteria, procedures, and methods in the current study were similar to our 
previous trial in patients not receiving ART [5]. Participants were instructed to start ART, as 
chosen by the primary HIV provider, and the study drug together at study entry. Study visits 
occurred at Weeks 0, 8, 24, and 48. No restrictions were made on the ART components or 
initial CD4 cell count. The primary endpoint was change in brachial artery FMD was 
measured using B-mode ultrasound after 5 minutes of forearm cuff occlusion to a supra-
systolic pressure, as previously described [5]. All scans were performed by a certified 
sonographer and read at the University of Wisconsin, the brachial artery reactivity testing 
reading center for the NHLBI HIV-CVD collaborative, by a single reader [5]. This trial was 
approved by the Indiana University Institutional Review Board; all participants provided 
written, informed consent. The use of pentoxifylline for the purpose of reducing 
inflammation and improving endothelial function is unlabeled and considered 
investigational.
Linear mixed-effects models were constructed to evaluate changes in FMD and the 
circulating biomarkers both between groups and over time. Additional models were 
constructed to evaluate the effects of individual biomarkers (listed in Table 1), baseline 
brachial artery diameter, CD4 cell count, and HIV-1 RNA levels on changes in FMD. We 
also constructed linear mixed effects models assessing treatment group by week interactions 
and including HIV-1 RNA levels at each study visit as a covariate. Two-sided P-values <0.05 
were considered statistically significant.
We enrolled 19 participants (10 in the PTX group, 9 in the placebo group). At weeks 8, 24, 
and 48, the numbers of participants remaining in the PTX and placebo arms were, 
respectively, 9 and 7, 8 and 6, and 4 and 5. The baseline characteristics of the enrolled 
participants are shown in Table 1. The two study groups were balanced. The majority of the 
study participants were black men with over half being current smokers. Table 1 shows the 
baseline brachial artery diameter, FMD, and nitroglycerin-mediated dilation (NTGMD) 
values at each time point. The changes in FMD (SD) in the PTX vs. the placebo groups at 
weeks 8, 24, and 48 were, respectively, −3.60% (2.54) vs. 1.91% (2.46), 0.72% (3.71) vs. 
1.07% (1.77), and 0.01 (3.22) vs. 2.23 (1.42). In all models constructed comparing these 
changes in FMD, even after adjustment for changes in HIV-1 RNA levels, we did not find 
significant differences between the PTX and placebo groups at any time point. There were 
also no significant changes between groups or over time in all models for nitroglycerin-
mediated dilation (NTGMD).
In our models assessing the changes in the circulating biomarkers, we found smaller 
declines from baseline in the PTX group vs. the placebo group in levels of monocyte 
chemoattractant protein-1 (MCP-1, pg/mL) [week 8: −68.18 (83.61) vs. −242.64 (180.66), 
P=0.01; week 24: −30.04 (129.17) vs. −225.71 (181.28), P=0.027; and week 48: −61.90 
(113.69) vs. −202.02 (185.62), P=0.077] and interleukin-6 (IL-6, pg/mL) [week 8: −1.27 
(1.57) vs. −2.73 (3.91), P=0.30; week 24: −0.29 (2.23) vs. −2.28 (3.46), P=0.033; and week 
48: −0.12 (0.41) vs. −3.13 (3.26) (P=0.045) but trends towards greater declines in levels of 
asymmetric dimethylarginine (ADMA, µmol/L) in the PTX group compared to the placebo 
group [week 8: −0.27 (0.17) vs. −0.16 (0.12), P=0.12; week 24: −0.31 (0.19) vs. −0.15 
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(0.07), P=0.03; and week 48: −0.35 (0.25) vs. −0.18 (0.15), P=0.06]. There were no 
significant changes between groups in the other biomarkers assessed at any time point.
There was one serious adverse event in the PTX group (suicidal ideation with overdose of a 
non-study drug which did not result in death) but none in the placebo group. There was a 
non-significantly higher number of gastrointestinal adverse events (nausea, flatus, diarrhea) 
with PTX (6 of 10 participants) compared to placebo (2 of 9 participants), none of which 
were treatment-limiting.
In this pilot, randomized, placebo-controlled trial, we did not find that PTX improved 
endothelial function in HIV-infected patients over the first year of ART. These results are in 
line with our previous trial in patients not receiving ART. However, in the current trial, we 
found that PTX may attenuate reductions in MCP-1 and IL-6 and possibly greater reductions 
in ADMA compared to placebo. We did not find any significant effects of PTX on sTNFR1 
as we had in our previous trial of PTX in patients not receiving ART. To our knowledge, 
these potential effects of PTX on the proatherogenic molecules MCP-1, IL-6, and ADMA 
have not previously been described. Although we cannot fully explain these latter results, 
these data add to our previous trial in those not receiving ART that PTX may have mixed 
and potentially adverse effects on inflammatory and endothelial activation pathways. Our 
results are limited by the small sample size, so they must be considered exploratory as we 
cannot exclude the possibility a larger, longer study or one that involved patients chronically 
treated with ART may have found an effect of PTX on vascular function. We acknowledge 
that the numbers of statistical tests performed may have led to false positive findings, 
especially in regards to the biomarker comparisons.
Because PTX is considered safe and very well-tolerated [5–7], it has been considered an 
ideal anti-inflammatory agent for chronic inflammatory conditions. For this reason, it is 
currently being studied in trials in HIV-uninfected patients for non-alcoholic steatohepatitis, 
irritable bowel syndrome, chronic kidney disease, and congestive heart failure 
(ClinicalTrials.gov). However, the lack of improvement in endothelial function and the 
potentially worrisome effects on several proatherogenic inflammatory molecules in our trials 
should be considered before using PTX in future trials in HIV-infected patients.
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